Downloads: 675

Files in This Item:
File Description SizeFormat 
ten.tea.2012.0634.pdf509.01 kBAdobe PDFView/Open
Title: Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers.
Authors: Morimoto, Naoki  kyouindb  KAKEN_id  orcid (unconfirmed)
Yoshimura, Kenichi
Niimi, Miyuki
Ito, Tatsuya  kyouindb  KAKEN_id
Aya, Rino  kyouindb  KAKEN_id
Fujitaka, Junpei
Tada, Harue  kyouindb  KAKEN_id
Teramukai, Satoshi
Murayama, Toshinori  KAKEN_id
Toyooka, Chikako
Miura, Kazumi
Takemoto, Satoru
Kanda, Norikazu
Kawai, Katsuya  KAKEN_id
Yokode, Masayuki  kyouindb  KAKEN_id
Shimizu, Akira  kyouindb  KAKEN_id
Suzuki, Shigehiko  kyouindb  KAKEN_id
Author's alias: 森本, 尚樹
Issue Date: 26-Jul-2013
Publisher: Mary Ann Liebert, Inc.
Journal title: Tissue engineering. Part A
Volume: 19
Issue: 17-18
Start page: 1931
End page: 1940
Abstract: Chronic skin ulcers such as diabetic ulcers and venous leg ulcers are increasing and are a costly problem in healthcare. We have developed a novel artificial dermis, collagen/gelatin sponge (CGS), which is capable of sustained release of basic fibroblast growth factor (bFGF) for more than 10 days. The objective of this study was to investigate the safety and efficacy of CGS impregnated with bFGF in the treatment of chronic skin ulcers. Patients with chronic skin ulcers that had not healed in at least 4 weeks were treated with CGS impregnated with bFGF at 7 or 14 μg/cm(2) after debridement, and the wound bed improvement was assessed 14 days after application. Wound bed improvement was defined as a granulated and epithelialized area on day 14 with a proportion to the baseline wound area after debridement of 50% or higher. The wound area, the wound area on day 14, and the granulation area on day 14 were independently measured by blinded reviewers in a central review using digital images of wounds taken with a calibrator. Patients were followed up until 28 days after application to observe the adverse reactions related to the application of CGS. From May 2010 to June 2011, 17 patients were enrolled and, in 16 patients, the wound bed improved. Among the randomized patients in step 2, no significant difference was seen between the low-dose group and the high-dose group. No serious adverse reactions were observed. Adverse reactions with a clear causal relationship to the study treatment were mild and patients quickly recovered from them. This study is the first-in-man clinical trial of CGS and showed the safety and efficacy of CGS impregnated with bFGF in the treatment of chronic skin ulcers. This combination therapy could be a promising therapy for chronic skin ulcers.
Rights: © 2013 Mary Ann Liebert, Inc.
"Tissue Engineering Part A" is available online at:
DOI(Published Version): 10.1089/ten.TEA.2012.0634
PubMed ID: 23541061
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.